<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04883931</url>
  </required_header>
  <id_info>
    <org_study_id>KA21/65</org_study_id>
    <nct_id>NCT04883931</nct_id>
  </id_info>
  <brief_title>Mother Milk as a Eye Drop &amp; Premature Retinopathy</brief_title>
  <official_title>The Effect of Using Breast Milk as a Topical Ophthalmic Drop on Retinopathy of Prematurity. Randomized Placebo-controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baskent University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baskent University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the effect of using breast milk as eye drops on ROP&#xD;
      (Retinopathy of prematurity) disease observed in less then 32 weeks gestational age preterm&#xD;
      babies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: Prospective randomized placebo controlled trial Setting/Participants: Premature&#xD;
      babies who are at high risk for retinopathy of prematurity (ROP) during their stay in the&#xD;
      neonatal intensive care unit (NICU). The study will be carried out at Baskent University and&#xD;
      it is planned that 70 participants will be included in the study.&#xD;
&#xD;
      Study Interventions and Measures: After the randomization of the patients, 0.5 ml breast milk&#xD;
      of the babies' own mothers will drop on the eye to the intervention group twice a day. IN the&#xD;
      control group, %0.9 normal saline will drop as same amount. Primary outcome is any stage of&#xD;
      ROP, secondary outcome is severe ROP (laser requiring ROP).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 12, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Porspective Randomized Placebo Controlled Trail</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Participant and Ophthalmologist who is the responsible the follow -up the ROP stages will be blind in the study. The neonatologist who is responsible for the care and follow-up of the patients will not be blind.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Retinopathy of Prematurity</measure>
    <time_frame>by 55 weeks post menstrual age</time_frame>
    <description>Number of participants with any stage of ROP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinopathy of Prematurity</measure>
    <time_frame>by 55 weeks post menstrual age</time_frame>
    <description>Number of participants with laser requiring - severe ROP</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Retinopathy of Prematurity</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>With in 48-72 hour after birth, infants will receive 0.5 ml breast milk for own mother as a eye drop twice in a day until the discharge or need for laser coagulation. Fresh milk was used as eye drop ( not exceed 6 hours after milking).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>With in 48-72 hour after birth, infants will receive 0.5 ml 0.9% normal saline as a eye drop twice in a day until the discharge or need for laser coagulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>0.5 ml 0.9% normal saline will drop on both eyes twice in a day.</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Breast milk</intervention_name>
    <description>0.5 ml breast milk from all infant's own mother will drop both eyes twice in a day</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infants born between 22 and 32 gestational age weeks or under 1500 gr birth weight.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Infant death before first examination for ROP&#xD;
&#xD;
          -  parents who want to leave from the study&#xD;
&#xD;
          -  Contraindications for breast milk use (Active HIV infection, Active tuberculosis, CMV&#xD;
             infection)&#xD;
&#xD;
          -  Inborn error of metabolism like galactosemia.&#xD;
&#xD;
          -  Congenital eye development disorders like agenesis, or situations that do not allow&#xD;
             retina examination.&#xD;
&#xD;
          -  other lethal congenital molformations&#xD;
&#xD;
          -  congenital infections that affect the retina like TORCH infections.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Weeks</minimum_age>
    <maximum_age>32 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Musa Silahli</last_name>
    <phone>+905342961110</phone>
    <email>msilahli@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Baskent University</name>
      <address>
        <city>Konya</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Musa Silahli</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 7, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baskent University</investigator_affiliation>
    <investigator_full_name>Musa Silahli</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Breast milk</keyword>
  <keyword>Retinopathy of Prematurity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Retinopathy of Prematurity</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

